RxDoctor Payments DataLook up a doctor →

Brent Hella, MD

Internal Medicine · Fargo, NDNPI 1245286988

Payments from drug & device makers

$894,086in general payments, 2019–2025

Across 1,224 payments — averaging $730.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$473K
  • Boehringer Ingelheim$380K
  • Boehringer Ingelheim International GmbH$20K
  • Boehringer Ingelheim France S.a.s.$11K
  • AstraZeneca$8K
  • Merck$103
  • plus $780 from 26 others

What the payments were for

  • Travel & lodging$1,26846%
  • Food & beverage$1,51954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$894,086 in reported general payments places this provider in the 95th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$114,237
Medicare patients
298
Services billed
8,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide613$665,577
MounjaroTirzepatide186$209,756
EliquisApixaban117$98,076
AdbryTralokinumab-Ldrm13$49,468
XareltoRivaroxaban22$21,570
TrulicityDulaglutide16$21,047
Tresiba Flextouch U-100Insulin Degludec25$19,057
JanuviaSitagliptin Phosphate16$16,858
JardianceEmpagliflozin17$15,003
Bydureon BciseExenatide Microspheres16$12,435
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,228
LinzessLinaclotide15$7,723
Liothyronine Sodium169$7,529
Levothyroxine Sodium439$5,896
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81$665,577613 claims
PfizerEliquis$52$98,076117 claims
MerckJanuvia$103$16,85816 claims
Boehringer IngelheimJardiance$380,257$15,00317 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$39$12,22814 claims
AbbVieLinzess, Armour Thyroid$51$9,97230 claims
GSKShingrix$41$2,88113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →